US equities |
GOOGL $324.89 ▲+0.00% GOOG $321.89 ▲+0.00% MU $983.23 ▲+0.00% SNDK $1,404.77 ▲+0.00% SKHY $164.70 ▲+0.00% LITE $913.95 ▲+0.00% MSFT $531.01 ▲+0.00% INTC $95.53 ▲+0.00%
FinancialContent

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2387 UNCHANGED
Delayed Quote Updated: 8:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
Via ACCESS Newswire
News headline image
US Stocks Likely To Open Higher, Continuing Record-Setting Advances: June Has Never Seen An All-Time High Since 1950, Highlights Expert ↗
U.S. futures rose on Monday after a record close on Friday. Futures of major benchmark indices were trading higher. 
Via Benzinga
News headline image
Progress Software, Exicure And 3 Stocks To Watch Heading Into Monday ↗
U.S. stock futures up, focus on PRGS, XCUR, QMCO earnings. VERO jumps 43.6% after stake increase, IGC reports positive results. Check out Cramer's oil pick. Photo: Shutterstock. 
Via Benzinga
News headline image
Insights Ahead: IGC Pharma's Quarterly Earnings ↗
 
Via Benzinga
News headline image
IGC Pharma Reports Third Quarter Fiscal 2025 Results
Via ACCESS Newswire
News headline image
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
Via ACCESS Newswire
News headline image
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Via ACCESSWIRE
News headline image
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon
Via ACCESS Newswire
News headline image
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market
Via ACCESS Newswire
News headline image
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
Via ACCESS Newswire
News headline image
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
IGC Pharma Welcomes Strategic Investment from Advisors
Via ACCESS Newswire
News headline image
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
Via ACCESS Newswire
News headline image
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
Via ACCESS Newswire
News headline image
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
Via ACCESS Newswire
News headline image
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
Via ACCESS Newswire
News headline image
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"
Via ACCESS Newswire
News headline image
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
Via ACCESS Newswire
News headline image
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
Via ACCESS Newswire
News headline image
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
Via ACCESS Newswire
News headline image
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
Via ACCESS Newswire
News headline image
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
Via ACCESS Newswire
News headline image
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
Via ACCESSWIRE
News headline image
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
Via ACCESSWIRE
News headline image
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial ↗
 
Via Benzinga
News headline image
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >